Literature DB >> 20180941

The anti-protozoal drug pentamidine blocks KIR2.x-mediated inward rectifier current by entering the cytoplasmic pore region of the channel.

T P de Boer1, L Nalos, A Stary, B Kok, M J C Houtman, G Antoons, T A B van Veen, J D M Beekman, B L de Groot, T Opthof, M B Rook, M A Vos, M A G van der Heyden.   

Abstract

BACKGROUND AND
PURPOSE: Pentamidine is a drug used in treatment of protozoal infections. Pentamidine treatment may cause sudden cardiac death by provoking cardiac arrhythmias associated with QTc prolongation and U-wave alterations. This proarrhythmic effect was linked to inhibition of hERG trafficking, but not to acute block of ion channels contributing to the action potential. Because the U-wave has been linked to the cardiac inward rectifier current (I(K1)), we examined the action and mechanism of pentamidine-mediated I(K1) block. EXPERIMENTAL APPROACH: Patch clamp measurements of I(K1) were made on cultured adult canine ventricular cardiomyocytes, K(IR)2.1-HEK293 cells and K(IR)2.x inside-out patches. Pentamidine binding to cytoplasmic amino acid residues of K(IR)2.1 channels was studied by molecular modelling. KEY
RESULTS: Pentamidine application (24 h) decreased I(K1) in cultured canine cardiomyocytes and K(IR)2.1-HEK293 cells under whole cell clamp conditions. Pentamidine inhibited I(K1) in K(IR)2.1-HEK293 cells 10 min after application. When applied to the cytoplasmic side under inside-out patch clamp conditions, pentamidine block of I(K1) was acute (IC(50)= 0.17 microM). Molecular modelling predicted pentamidine-channel interactions in the cytoplasmic pore region of K(IR)2.1 at amino acids E224, D259 and E299. Mutation of these conserved residues to alanine reduced pentamidine block of I(K1). Block was independent of the presence of spermine. K(IR)2.2, and K(IR)2.3 based I(K1) was also sensitive to pentamidine blockade. CONCLUSIONS AND IMPLICATIONS: Pentamidine inhibits cardiac I(K1) by interacting with three negatively charged amino acids in the cytoplasmic pore region. Our findings may provide new insights for development of specific I(K1) blocking compounds.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20180941      PMCID: PMC2850409          DOI: 10.1111/j.1476-5381.2010.00658.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  54 in total

1.  Biological pacemaker created by gene transfer.

Authors:  Junichiro Miake; Eduardo Marbán; H Bradley Nuss
Journal:  Nature       Date:  2002-09-12       Impact factor: 49.962

2.  Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome.

Authors:  N M Plaster; R Tawil; M Tristani-Firouzi; S Canún; S Bendahhou; A Tsunoda; M R Donaldson; S T Iannaccone; E Brunt; R Barohn; J Clark; F Deymeer; A L George; F A Fish; A Hahn; A Nitu; C Ozdemir; P Serdaroglu; S H Subramony; G Wolfe; Y H Fu; L J Ptácek
Journal:  Cell       Date:  2001-05-18       Impact factor: 41.582

3.  Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam.

Authors:  Esther J S K Lai A Fat; Martinus A Vrede; Ramon M Soetosenojo; Rudy F M Lai A Fat
Journal:  Int J Dermatol       Date:  2002-11       Impact factor: 2.736

4.  Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome).

Authors:  Martin Tristani-Firouzi; Judy L Jensen; Matthew R Donaldson; Valeria Sansone; Giovanni Meola; Angelika Hahn; Said Bendahhou; Hubert Kwiecinski; Anna Fidzianska; Nikki Plaster; Ying-Hui Fu; Louis J Ptacek; Rabi Tawil
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 5.  Pentamidine uptake and resistance in pathogenic protozoa: past, present and future.

Authors:  Patrick G Bray; Michael P Barrett; Stephen A Ward; Harry P de Koning
Journal:  Trends Parasitol       Date:  2003-05

6.  Ion-blocking sites of the Kir2.1 channel revealed by multiscale modeling.

Authors:  Kaihsu Tai; Phillip J Stansfeld; Mark S P Sansom
Journal:  Biochemistry       Date:  2009-09-15       Impact factor: 3.162

7.  Effects of acute intravenous administration of pentamidine, a typical hERG-trafficking inhibitor, on the cardiac repolarization process of halothane-anesthetized dogs.

Authors:  Hirofumi Yokoyama; Yuji Nakamura; Hiroshi Iwasaki; Yukitoshi Nagayama; Kiyotaka Hoshiai; Yoshitaka Mitsumori; Atsushi Sugiyama
Journal:  J Pharmacol Sci       Date:  2009-08-01       Impact factor: 3.337

8.  Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions.

Authors:  Daniela Ponce-Balbuena; Angélica López-Izquierdo; Tania Ferrer; Aldo A Rodríguez-Menchaca; Iván A Aréchiga-Figueroa; José A Sánchez-Chapula
Journal:  J Pharmacol Exp Ther       Date:  2009-08-04       Impact factor: 4.030

9.  Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters.

Authors:  Xin Ming; Wujian Ju; Huali Wu; Richard R Tidwell; James E Hall; Dhiren R Thakker
Journal:  Drug Metab Dispos       Date:  2008-10-29       Impact factor: 3.922

10.  Action potential clamp and chloroquine sensitivity of mutant Kir2.1 channels responsible for variant 3 short QT syndrome.

Authors:  Aziza El Harchi; Mark J McPate; Yi hong Zhang; Henggui Zhang; Jules C Hancox
Journal:  J Mol Cell Cardiol       Date:  2009-03-10       Impact factor: 5.000

View more
  21 in total

1.  Inhibition of inwardly rectifying Kir2.x channels by the novel anti-cancer agent gambogic acid depends on both pore block and PIP2 interference.

Authors:  Daniel Scherer; Benedikt Schworm; Claudia Seyler; Panagiotis Xynogalos; Eberhard P Scholz; Dierk Thomas; Hugo A Katus; Edgar Zitron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-04-02       Impact factor: 3.000

2.  Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224.

Authors:  Panagiotis Xynogalos; Claudia Seyler; Daniel Scherer; Christoph Koepple; Eberhard P Scholz; Dierk Thomas; Hugo A Katus; Edgar Zitron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-09-04       Impact factor: 3.000

3.  Molecular determinants of pentamidine-induced hERG trafficking inhibition.

Authors:  Adrienne T Dennis; Lu Wang; Hanlin Wan; Drew Nassal; Isabelle Deschenes; Eckhard Ficker
Journal:  Mol Pharmacol       Date:  2011-11-01       Impact factor: 4.436

4.  Pentamidine analogs as inhibitors of [(3)H]MK-801 and [(3)H]ifenprodil binding to rat brain NMDA receptors.

Authors:  Michael L Berger; Dorota Maciejewska; Jean Jacques Vanden Eynde; Madhusoodanan Mottamal; Jerzy Żabiński; Paweł Kaźmierczak; Mateusz Rezler; Ivana Jarak; Ivo Piantanida; Grace Karminski-Zamola; Annie Mayence; Patrick Rebernik; Arvind Kumar; Mohamed A Ismail; David W Boykin; Tien L Huang
Journal:  Bioorg Med Chem       Date:  2015-06-14       Impact factor: 3.641

5.  Mechanisms for Kir channel inhibition by quinacrine: acute pore block of Kir2.x channels and interference in PIP2 interaction with Kir2.x and Kir6.2 channels.

Authors:  Angélica López-Izquierdo; Iván A Aréchiga-Figueroa; Eloy G Moreno-Galindo; Daniela Ponce-Balbuena; Martín Rodríguez-Martínez; Tania Ferrer-Villada; Aldo A Rodríguez-Menchaca; Marcel A G van der Heyden; José A Sánchez-Chapula
Journal:  Pflugers Arch       Date:  2011-07-22       Impact factor: 3.657

6.  KCNJ2 mutation in short QT syndrome 3 results in atrial fibrillation and ventricular proarrhythmia.

Authors:  Makarand Deo; Yanfei Ruan; Sandeep V Pandit; Kushal Shah; Omer Berenfeld; Andrew Blaufox; Marina Cerrone; Sami F Noujaim; Marco Denegri; José Jalife; Silvia G Priori
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

7.  Inhibition of Kir4.1 potassium channels by quinacrine.

Authors:  Leticia G Marmolejo-Murillo; Iván A Aréchiga-Figueroa; Meng Cui; Eloy G Moreno-Galindo; Ricardo A Navarro-Polanco; José A Sánchez-Chapula; Tania Ferrer; Aldo A Rodríguez-Menchaca
Journal:  Brain Res       Date:  2017-03-11       Impact factor: 3.252

8.  ML418: The First Selective, Sub-Micromolar Pore Blocker of Kir7.1 Potassium Channels.

Authors:  Daniel R Swale; Haruto Kurata; Sujay V Kharade; Jonathan Sheehan; Rene Raphemot; Karl R Voigtritter; Eric E Figueroa; Jens Meiler; Anna L Blobaum; Craig W Lindsley; Corey R Hopkins; Jerod S Denton
Journal:  ACS Chem Neurosci       Date:  2016-05-24       Impact factor: 4.418

Review 9.  Cardiac and renal inward rectifier potassium channel pharmacology: emerging tools for integrative physiology and therapeutics.

Authors:  Daniel R Swale; Sujay V Kharade; Jerod S Denton
Journal:  Curr Opin Pharmacol       Date:  2013-11-26       Impact factor: 5.547

10.  Inhibiting the clathrin-mediated endocytosis pathway rescues K(IR)2.1 downregulation by pentamidine.

Authors:  Rosanne Varkevisser; Marien J C Houtman; Maaike Waasdorp; Joyce C K Man; Raimond Heukers; Hiroki Takanari; Ralph G Tieland; Paul M P van Bergen En Henegouwen; Marc A Vos; Marcel A G van der Heyden
Journal:  Pflugers Arch       Date:  2012-11-29       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.